[Video] Protuoso Biosciences exited stealth this past week with the goal of developing multifunctional MUXBODY biologics, fusion proteins that integrate diverse modalities into a single therapy

Co-Founder & CEO Willie Xiang discusses the platform and the company's progress to getting them into the clinic. Current programs target cardiometabolic diseases and solid tumors.

Watch the interview here:

Protuoso Biosciences exited stealth this past week with the goal of developing multifunctional MUXBODY biologics, fusion proteins that integrate diverse modalities into a single therapy